Innovation paired with material risk.

Nemaura’s investment story combines a differentiated device concept with minimal historical revenue, recurring losses, commercialization uncertainty and an OTC market transition.

Market symbolNMRDOTC Markets

Formerly Nasdaq listed

AUDITED SNAPSHOT

FY2023 figures in context.

The latest audited annual figures located for this project cover the year ended March 31, 2023—not current 2026 performance.

Sales$77,044

Compared with $503,906 in FY2022.

Net loss-$14.14M

Recurring losses remained substantial.

Cash$10.11M

Cash and equivalents at March 31, 2023.

Small organization

Public profiles have produced conflicting employee snapshots, from roughly eight to approximately 36–38 people. No single estimate is presented here as a current audited headcount.

Development stage

Operations have centered on partnerships, licensing, clinical pilots, regulatory work and manufacturing scale-up.

Pre-profitability

Minimal historical product sales and recurring losses make capital access and commercialization execution central risks.

LISTING HISTORY

From Nasdaq to the OTC market.

2018

Nasdaq listing

NMRD moved onto the Nasdaq Capital Market.

→

2023

Compliance pressure

Low market capitalization, trading volume and related listing conditions created compliance challenges.

→

2024

OTC transition

Nasdaq trading was suspended in January 2024; the company accepted delisting and moved to OTC markets.

↗

POTENTIAL CATALYSTS

What could support progress

Broader commercialization of sugarBEAT
New jurisdictional approvals
Strategic partnerships and licensing
Manufacturing scale and completed orders
Evidence from digital-health programs

MATERIAL RISKS

What may limit the business

Minimal historical revenue
Recurring operating losses
Going-concern uncertainty
Regulatory and clinical delays
OTC liquidity and capital-raising risk

High-risk profile

The FY2023 auditor’s report raised substantial doubt about the company’s ability to continue as a going concern. This academic summary is not investment advice.

Read the SEC filing ↗

Independent educational project

This website is not affiliated with Nemaura Medical Inc. and does not provide medical or investment advice.